


PERSONAL INFORMATION

Alberto Zanetto



Birth date 14/10/1988 | Italian.

CURRENT POSITION

From 14/06/2022
ongoing

Assistant professor in gastroenterology (RTDa)

Gastroenterology, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Italy

EDUCATION AND TRAINING

- 12/12/2023 **National Scientific qualification as associate professor** or the disciplinary field of 06/D4 - Skin, infectious and gastrointestinal diseases
- From 15/10/2021 to 13/06/2022 **Research bursary**, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Italy.
- 21/02/2022 **PhD in Clinical and Experimental Oncology and Immunology**, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Italy.
- From 01/01/2021 to 30/09/2021 **Clinical research training** at Hepatic hemodynamic Lab, Gastroenterology Unit, Modena University Hospital, Italy.
- 14/06/2019 **Transplant Hepatologist** certification given by the Italian Association for the Study of the Liver.
- From 01/10/2018 to 30/09/2020 **Clinical research fellowship at** Digestive Diseases Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- From 01/10/2018 to 30/09/2021 **PhD course in Clinical and Experimental Oncology and Immunology**, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Italy.
- From 01/03/2016 to 01/06/2016 **Visiting scientist** at Viral Hepatitis Lab, Liver Unit, Hospital Clinic, Barcelona, Spain.
- From 09/12/2014 to 10/12/2019 **Fellowship in gastroenterology** at University of Padua, Italy.
- 18/02/2014 **License to practice as medical doctor.**

From 01/09/2013 **Research bursary** at Department of Surgery, Oncology, and
to 01/12/2014 Gastroenterology, Padua University Hospital, Italy.

14/07/2013 **Medical degree** at University of Padua, Italy.

CLINICAL ACTIVITY (Gastroenterology and Multivisceral Transplant Unit, Padova University hospital)

Gastroenterology and hepatology:

1. Clinical management of inpatients with GI and/or liver acute and/or chronic diseases.
2. Outpatients clinic with specific interest in hepatology, cirrhosis and portal hypertension, hepatocellular carcinoma, viral hepatitis, vascular liver diseases.

Transplantation:

1. Evaluation of liver transplant candidates.
2. Clinical management of patients awaiting liver transplantation.
3. Clinical follow-up after liver transplantation, management of immunosuppression and complications.

Techniques:

1. Upper and lower endoscopy (diagnostic and therapeutics).
2. Liver and abdominal ultrasound.
3. Diagnostic and therapeutic paracentesis.
4. Evaluation of liver stiffness (transient elastography and shear-wave elastography).
5. Ultrasound guidance during trans-jugular liver biopsy and placement of TIPS (trans-jugular intra-hepatic portosystemic shunt).
6. Trans-jugular puncture, measurement of the hepatic vein pressure gradient (HVPG), right heart catheterization, revision/dilatation of TIPS, trans-jugular liver biopsy.

TRANSLATIONAL RESEARCH ACTIVITY

Translation project regarding chronic viral hepatitis HBV e HCV:

1. Isolation of *PBMC* (cellule mononucleate sangue periferico).
2. Cytofluorimetry with specific staining for natural killer NK cells and T lymphocytes.
3. Cellular culture models.
4. PCR for the detection of cccDNA.
5. Ultra deep sequencing (regions NS3, NS5A, NS5B of HCV RNA).

Translation project regarding hemostasis, cirrhosis, and liver transplantation:

1. Rotational thromboelastometry (ROTEM) and elastography (TEG).
2. Lumiaggregometry (Chronolog 700).
3. Assessment of platelet adhesion by PFA-200.
4. Evaluation of von Willebrand factor, pro and anticoagulant factors, pro and antifibrinolytic factors.
5. Thrombin generation with and without thrombomodulin.

SCIENTIFIC ACTIVITY

1. Summary of publications

Number of full papers as AUTHOR: 119 (mostly related to cirrhosis and its complications, portal hypertension, and liver transplantation)


Number of full papers as FIRST AUTHOR/LAST AUTHOR/CORRESPONDING AUTHOR: 57 (48%)

Number of full papers as MEMBER OF THE WORKING GROUP: 7


Number of BOOK CHAPTER: 5

H-index (Scopus): 25; Totale citazioni (Scopus): 1763

Citation by year (Scopus):



Number of full paper published per year (Scopus):



Full papers in peer-reviewed journals published as author:

1. "Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease" Dominik N, Scheiner B, **Zanetto A**, Balcar L, Semmler G, Campello E, Schwarz M, Paternostro R, Simbrunner B, Hofer BS, Stättermayer AF, Pinter M, Trauner M, Quehenberger P, Simioni P, Reiberger T, Mandorfer M, APT 2024 (accepted for publication).
2. "Letter to the editor: are we comparing apples with oranges?". **Zanetto A***, Campello E, Senzolo M, Simioni P (***corresponding author**). HEPATOLOGY 2024. DOI: 10.1097/HEP.0000000000000799.
3. "Prognostic models in end stage liver disease". Ferrarese A, Bucci M, **Zanetto A**, Senzolo M, Germani G, Gambato M, Russo FP, Burra P. Best Pract Res Clin Gastroenterol. 2023. DOI: 10.1016/j.bpg.2023.101866.
4. "PFA-100 in advanced chronic liver disease: End of the story?" **Zanetto A***, Simioni P (***corresponding author**). JHEP Rep. 2023. DOI: 10.1016/j.jhepr.2023.100967.
5. "The role of an integrated referral program for patients with liver disease: A network between hub and spoke centers". Germani G, Ferrarese A, D'Arcangelo F, Russo FP, Senzolo M, Gambato M, **Zanetto A**, Cillo U, Feltracco P, Persona P, Serra E, Feltrin G, Carretta G, Capizzi A, Donato D, Tessarin M, Burra P. United European Gastroenterol J. 2023. DOI: 10.1002/ueg2.12475.
6. "Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort". Kondili LA*, **Zanetto A***, Quaranta MG, Ferrigno L, Panetta V, Calvaruso V, Zignego AL, Brunetto MR, Raimondo G, Biliotti E, Ieluzzi D, Iannone A, Madonia S, Chemello L, Cavalletto L, Coppola C, Morisco F, Barbaro F, Licata A, Federico A, Cerini F, Persico M, Pompili M, Ciancio A, Piscaglia F, Chessa L, Giacometti A, Invernizzi P, Brancaccio G, Benedetti A, Baiocchi L, Gentile I, Coppola N, Nardone G, Craxì A, Russo FP; PITER Collaborating Investigators (***equally contributed and joint first authors**). United European Gastroenterol J. 2023. DOI: 10.1002/ueg2.12496.
7. "Mortality related to HCV and other chronic liver diseases in Veneto (Italy), 2008-2021: Changes in trends and age-period-cohort effects". Casotto V, Amidei CB, Saia M, Gregori D, **Zanetto A**, Fedeli U, Russo FP. Liver Int. 2023. DOI: 10.1111/liv.15798.
8. "von Willebrand factor does not predict short-term mortality in ACLF". **Zanetto A**, Campello E, Bulato C, Simioni P (***corresponding author**). Liver Int. 2023. DOI: 10.1111/liv.15802.
9. "A rare cause of painful hepatomegaly". **Zanetto A**, Senzolo M, Pelizzaro F, Mescoli C, Rizzo S. (***corresponding author**). J Hepatol. 2023. DOI: 10.1016/j.jhep.2023.09.015.
10. "Bacterial infections predispose to the development of portal vein thrombosis in patients with decompensated cirrhosis". **Zanetto A**, Campello E, Simioni P, Senzolo M (***corresponding author**). Dig Liver Dis. 2023. DOI: 10.1016/j.dld.2023.11.007.
11. "Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis". **Zanetto A**, Campello E, Bulato C, Willems R, Konings J, Roest M, Gavasso S, Nuozi G, Toffanin S, Zanaga P, Burra P, Russo FP, Senzolo M, de Laat B, Simioni P. J Thromb Haemost. 2023. DOI: 10.1016/j.jtha.2023.10.008.
12. "Toward a more precise prognostic stratification in acute decompensation of cirrhosis: The Padua model 2.0". **Zanetto A**, Pelizzaro F, Mion MM, Bucci M, Ferrarese A, Simioni P, Basso D, Burra P, Senzolo M. United European Gastroenterol J. 2023. DOI: 10.1002/ueg2.12472.
13. "Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients". Gambato M, Manuli C, Lynch EN, Battistella S, Germani G, Senzolo M, **Zanetto A**, Ferrarese A, Vitale A, Gringeri E, Cillo U, Burra P, Russo FP. Viruses. 2023. DOI: 10.3390/v15081702.

14. "Mean platelet volume is not a useful prognostic biomarker in patients with cirrhosis". **Zanetto A***, Campello E, Toffanin S, Russo FP, Senzolo M, Simioni P (***corresponding author**). *Dig Liver Dis*. 2023. DOI: 10.1016/j.dld.2023.08.001.
15. "Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC". Senzolo M, Shalaby S, Grasso M, Vitale A, Pizzirani E, Barbiero G, **Zanetto A**, Feltracco P, Simioni P, Burra P, Cillo U. *Hepatology*. 2023. DOI: 10.1097/HEP.0000000000000538.
16. "Mortality from chronic liver disease: Recent trends and impact of the COVID-19 pandemic". Fedeli U, Barbiellini Amidei C, Casotto V, Grande E, Saia M, **Zanetto A**, Russo FP. *World J Gastroenterol*. 2023. DOI: 10.3748/wjg.v29.i26.4166.
17. "Young gastroenterologists angle: Friends of the UEG young talent group consensus statement on the structure of young gastroenterology sections". Staudacher JJ, Burisch J, Sousa P, Salaga M, Pellino G, Sidiropoulos O, Groen MT, Mandorfer M, Schwabl P, Straume Z, Bîrlog C, Dugic A, Simsek C, Jovanovic J, Kani HT, Qejvani O, Fennessy AM, Gorcheva Z, Kral J, **Zanetto A**, Duricek M, Domislovic V, Acedo P, Schlosser S; friends of the Young Talent Group. *United European Gastroenterol J*. 2023. DOI: 10.1002/ueg2.12430.
18. "Multiple hepatic cysts in an adult male". **Zanetto A**, Pelizzaro F, Bellan E, Sbaraglia M. *Journal of Hepatology* 2023. DOI: doi.org/10.1016/j.jhep.2023.05.006.
19. "The role of antiviral prophylaxis in preventing HBV and HDV recurrence in the setting of liver transplantation". Battistella S, **Zanetto A**, Gambato M, Germani G, Senzolo M, Burra P, Russo FP. *Viruses*. 2023. DOI: 10.3390/v15051037.
20. "Liver transplantation in the frail patient" Tandon P, **Zanetto A**, Piano S, Heimbach JK, Dasarathy S. *Journal of Hepatology* 2023. DOI: 10.1016/j.jhep.2023.03.025.
21. "Changings and Challenges in Liver Transplantation for Nonalcoholic Fatty Liver Disease/ Steatohepatitis". Shalaby S, Battistella S, **Zanetto A**, Bizzaro D, Germani G, Russo FP, Burra P. *Clin Liver Dis* 2023. DOI: 10.1016/j.cld.2023.01.003.
22. "A step forward towards understanding dynamics of coagulation in patients with cirrhosis". **Zanetto A***, Simioni P (***corresponding author**). *Journal of Thrombosis and Haemostasis* 2023. DOI: 10.1016/j.jtha.2023.02.012.
23. "The evolving knowledge on primary hemostasis in patients with cirrhosis: a comprehensive review". **Zanetto A**, Campello E, Senzolo M, Simioni P. *HEPATOLOGY* 2023. DOI: 10.1097/HEP.0000000000000349.
24. "Influence of sex in alcohol-related liver disease: pre-clinical and clinical settings" Bizzaro D, Becchetti C, Trapani S, Lavezzo B, **Zanetto A**, D'Arcangelo F, Merli M, Lapenna L, Invernizzi F, Taliani G, Burra P, on behalf of the AISF Special Interest Group Gender in Hepatology. *UEG Journal* 2023. DOI: 10.1002/ueg2.12370.
25. "Current treatment strategies and future possibilities for sarcopenia in cirrhosis". Ebadi M, Burra P, **Zanetto A**, Montano-Loza AJ. *Journal of Hepatology* 2023. DOI: 10.1016/j.jhep.2023.01.031.
26. "Assessment of whole blood platelet aggregation in patients with cirrhosis: challenges and opportunities". **Zanetto A**, Campello E, Senzolo M, Simioni P. *Platelets* 2023. DOI: 10.1080/09537104.2023.2178823.
27. "Hemostasis in cirrhosis: understanding destabilizing factors during acute decompensation". **Zanetto A**, Northup P, Roberts L, Senzolo M. *Journal of Hepatology* 2023. DOI: 10.1016/j.jhep.2023.01.010.
28. "Liver Transplantation for NAFLD: indications and post-transplant management". Battistella S, D'Arcangelo F, Grasso M, **Zanetto A**, Gambato M, Germani G, Senzolo M, Russo FP, Burra P. *Clinical Mol Hepatol* 2022. DOI: 10.3350/cmh.2022.0392.
29. "Endovascular Assessment of Liver Hemodynamics in Cirrhotic Patients with Portal Hypertension". Garcia-Pagan JC, Gaba RC, Schepis F, Garcia-Tsao G, **Zanetto A**, Haskal ZJ, Perez-Campuzano V, Ferral H. *Journal of Vascular and Interventional Radiology* 2022. DOI: 10.1016/j.jvir.2022.12.014.

30. “von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF”. **Zanetto A***, Campello E, Bulato C, Burra P, Senzolo M, Simioni P (***corresponding author**). *Digestive and Liver Disease* 2022. DOI: 10.1016/j.dld.2022.10.001.
31. “Increased platelet ratio in patients with decompensated cirrhosis indicates higher risk of portal vein thrombosis” **Zanetto A**, Campello E, Burra P, Senzolo M, Simioni P. *Liver International* 2022. DOI: 10.1111/liv.15435.
32. “UEG Week and UEG Journal: a strong scientific liaison” **Zanetto A*** (***corresponding author**). *UEG Journal* 2022. DOI: 10.1002/ueg2.12312.
33. “Systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis” **Zanetto A**, Pelizzaro F, Campello E, Bulato C, Balcar L, Gu W, Gavasso S, Saggiorato G, Zeuzem S, Russo FP, Mandorfer M, Reiberger T, Trebicka J, Burra P, Simioni P, Senzolo M. *Journal of Hepatology* 2022. DOI: 10.1016/j.jhep.2022.09.005.
34. “Non-invasive tests for clinically significant portal hypertension after HCV cure” Semmler G, Lens S, Meyer EL, Baiges A, Alvarado-Tapias E, Llop E, Tellez L, Schwabl P, Mauro E, Escudè L, Diez C, Ibanez-Samaniego L, Puente A, Ignacio Fortea J, Abadía M, **Zanetto A**, Conthe A, Hernandez-Evole H, Sofia Luzko Scheid I, Jia J, Yoshij H, Francque SM, Tsochatzis EA, Russo FP, Crespo G, Forns X, Banares R, Villanueva C, Hernandez-Gea V, Reiberger T, Bosch J, Garcia-Pagan JC, Mandorfer M, a study by the Baveno Cooperation: an EASL consortium. *Journal of Hepatology* 2022. DOI: 10.1016/j.jhep.2022.08.025.
35. “Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: a validated prediction model” Vizzuti F, Celsa C, Calvaruso V, Enea M, Battaglia S, Turco L, Senzolo M, Nardelli S, Miraglia R, Roccarina D, Campani C, Saltini D, Caporali C, Indulti F, Gitto S, **Zanetto A**, Di Maria G, Bianchini M, Pecchini M, Aspite S, Di Bonaventura C, Citone M, Guasconi T, Di Benedetto F, Arena U, Fanelli F, Maruzzelli L, Riggio O, Burra P, Colecchia A, Villa E, Marra F, Cammà C, Schepis F. *HEPATOLOGY* 2022. DOI: 10.1002/hep.32704.
36. “Vascular liver diseases: A sex-oriented analysis of the literature” **Zanetto A**, Cossiga V, Shalaby S, Guarino M, Invernizzi F, Lapenna L, Becchetti C, Morisco F, Morelli MC, Merli M, Toniutto P, Burra P. *Digestive and Liver Disease* 2022. DOI: <https://doi.org/10.1016/j.dld.2022.07.005>.
37. “The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions” Deltenre P*, **Zanetto A***, Saltini D, Moreno C, Schepis F. (***equally contributed and joint first authors**). *HEPATOLOGY* 2022. DOI: 10.1002/hep.32596.
38. “Reply to Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis” Shalaby S, **Zanetto A**, Campello E, Gavasso S, Barbiero G, Battistel M, Feltracco P, Bizzaro D, Burra P, Simioni P, Senzolo M. *Platelets*. DOI: 10.1080/09537104.2022.2060499.
39. “Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections” **Zanetto A**, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, Burra P, Angeli P, Senzolo M, Simioni P. *JHEP Reports*. DOI: 10.1016/j.jhepr.2022.100493.
40. “Staging the pre-procedural prophylaxis in decompensated cirrhosis” **Zanetto A**, Campello E, Spiezia L, Burra P, Simioni P, Senzolo M. *Digestive and Liver Disease*. DOI: 10.1016/j.dld.2022.04.023.
41. “Sex bias in clinical trials in gastroenterology and hepatology”. Burra P, **Zanetto A**, Germani G. *Nat Rev Gastroenterol Hepatol*. DOI: 10.1038/s41575-022-00638-2.
42. “Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death”. **Zanetto A**, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, Tormene D, Burra P, Senzolo M, Simioni P. *Journal of Hepatology*. DOI: 10.1016/j.jhep.2022.03.009.

43. “Young GI angle. Challenges and opportunities as a trainee editor: The United European Gastroenterology journal experience”. Rodriguez-Lago I, Hollenbach M, Archibugi L, Ciocan D, Labanio D, Nuzzo A, Pawlak KM, **Zanetto A**, Melchior C. UEG Journal. DOI: 10.1002/ueg2.12222.
44. “The role of preoperative optimization of the nutritional status on the improvement of short-term outcomes after liver transplantation – a review of the literature and expert panel recommendations” Victor DW 3rd, **Zanetto A**, Montano-Loza AJ, Heimbach JK, Towey J, Spiro M, Raptid DA, Burra P. Clin Transplant. DOI: 10.1111/ctr.14647.
45. “COVID-19 and liver disease”: where are we now? Russo FP, Burra P, **Zanetto A**. Nat Rev Gastroenterol Hepatol. DOI: 10.1038/s41575-022-00607-9.
46. “Hemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications” **Zanetto A**, Campello E, Pelizzaro F, Farinati F, Burra P, Simioni P, Senzolo M. Liver International. DOI: 10.1111/liv.15183.
47. “Hepatocellular carcinoma in chronic viral hepatitis: where do we stand?” Russo FP*, **Zanetto A***, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. (***equally contributed and joint first authors**). International Journal of Molecular Science. DOI: 10.3390/ijms23010500.
48. “Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?” **Zanetto A***, Campello E, Spiezia L, Burra P, Simioni P, Senzolo M. (***corresponding author**) HEPATOLOGY. DOI: 10.1002/hep.32392.
49. “HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease” Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, **Zanetto A**, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Journal of Hepatology. DOI: 10.1016/j.jhep.2021.11.025.
50. “Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature”. Guarino M, Cossiga V, Becchetti C, Invernizzi F, Lapenna L, Lavezzo B, Lenci I, Merli M, Pasulo L, **Zanetto A**, Burra P, Morisco F; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2021. DOI: 10.1016/j.dld.2021.10.010.
51. “Recent advances in the management of acute variceal hemorrhage”. **Zanetto A**, Shalaby S, Feltracco P, Gambato M, Germani G, Russo FP, Burra P, Senzolo M. Journal of Clinical Medicine 2021. DOI: 10.3390/jcm10173818.
52. “New indications for liver transplantation”. **Zanetto A**, Shalaby S, Gambato M, Germani G, Senzolo M, Bizzaro D, Russo FP, Burra P. Journal of Clinical Medicine 2021. DOI: 10.3390/jcm10173867.
53. “The essential guide to manage the post liver transplanted patients: what hospital physicians and general practitioners should know”. Toniutto P, Germani G, Ferrarese A, Bitetto D, **Zanetto A**, Fornasiere E, Fumolo E, Shalaby S, Burra P. The American Journal of Medicine 2021. DOI: 10.1016/j.amjmed.2021.08.005.
54. “Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure”. Campello E*, **Zanetto A***, Bulato C, Maggiolo S, Spiezia L, Russo FP, Gavasso S, Mazzeo P, Tormene D, Burra P, Angeli P, Senzolo M, Simioni P (***equally contributed and joint first authors**). Liver International 2021. DOI: 10.1111/liv.15001.
55. “More pronounced hypercoagulable state and hypo-fibrinolysis in cirrhosis patients with versus without HCC”. **Zanetto A**, Campello E, Bulato C, Gavasso G, Saggiorato G, Shalaby S, Spiezia L, Cillo U, Farinati F, Russo FP, Burra P, Senzolo M, Simioni P. Hepatology Communications 2021. DOI: 10.1002/hep4.1781.
56. “Comparison of fondaparinux and low molecular weight heparin in the treatment of portal vein thrombosis in cirrhosis”. Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, **Zanetto A**, Sacerdoti D, Simioni P, Bombonato G, Burra B, Angeli P. The American Journal of Medicine 2021. DOI: 10.1016/j.amjmed.2021.05.013.

57. "Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!". **Zanetto A***, Senzolo M, Campello E, Bulato C, Gavasso S, Saggiorato G, Feltracco P, Farinati F, Russo FP, Burra P, Garcia-Tsao G, Simioni P. *Transplant International* 2021 (***corresponding author**). DOI: 10.1111/tri.13895.
58. "Reply to: Acute kidney injury in patients with decompensated cirrhosis". Campello E*, **Zanetto A***, Garcia-Tsao G, Simioni P (***equally contributed and joint first authors**). *Digestive and Liver Disease* 2021. DOI: 10.1016/j.dld.2021.03.034.
59. "Malnourished cirrhotic patient: what should we do?". Sciarrone SS, **Zanetto A**, Russo FP, Germani G, Gambato M, Battistella S, Pellone M, Shalaby S, Burra P, Senzolo M. *Minerva Gastroenterology* 2020. DOI: 10.23736/S2724-5985.20.02776-2.
60. "Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis". Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperis E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, **Zanetto A**, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. *GUT* 2021. DOI: 10.1136/gutjnl-2020-323663.
61. "Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis". **Zanetto A***, Senzolo M*, Campello E, Bulato C, Gavasso S, Shalaby S, Gambato M, Vitale A, Cillo U, Farinati F, Russo FP, Simioni P, Burra P. *Cancers* 2021 (***equally contributed and joint first authors**). DOI: 10.3390/cancers13051150.
62. "Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation". Shalaby S, Taborelli M, **Zanetto A**, Ferrarese A, D'Arcangelo F, Gambato M, Senzolo M, Russo FP, Germani G, Boccagni P, Ettorre GM, Baccarani U, Lauro A, Galatioto L, Rendina M, Petrara R, De Rossi A, Nudo F, Toti L, Fantola G, Vennarecci G, Risaliti A, Pinna AD, Gruttadauria S, Di Leo A, Rossi M, Tisone G, Zamboni F, Cillo U, Piselli P, Serraino D, Burra P. *Transplant International* 2021. DOI: 10.1111/tri.13831.
63. "Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis". Campello E*, **Zanetto A***, Radu C.M., Bulato C, Truma A, Spiezia L, Senzolo M, Garcia-Tsao G, Simioni P (***equally contributed and joint first authors**). *Digestive and Liver Disease* 2021. DOI: 10.1016/j.dld.2020.12.118.
64. "Drug induced liver injury: from pathogenesis to liver transplantation". Germani G, Battistella S, Ulinici D, **Zanetto A**, Shalaby S, Pellone M, Gambato M, Senzolo M, Russo FP, Burra P. *Minerva Gastroenterology* 2020. DOI: 10.23736/S1121-421X.20.02795-6.
65. "Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving anti-viral therapy." Battistella S, Lynch EN, Gambato M, **Zanetto A**, Pellone M, Shalaby S, Sciarrone S, Ferrarese A, Germani G, Senzolo M, Burra P, Russo FP. *Minerva Gastroenterology* 2020. DOI: 10.23736/S1121-421X.20.02791-9.
66. "Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma". Germani G, Battistella S, Ulinici D, **Zanetto A**, Shalaby S, Pellone M, Gambato M, Senzolo M, Russo FP, Burra P. *Minerva Gastroenterology* 2020. DOI: 10.23736/S1121-421X.20.02775-0.
67. "Management of portal hypertension severe complications". **Zanetto A**, Barbiero G, Battistella M, Sciarrone SS, Shalaby S, Pellone M, Battistella S, Gambato M, Germani G, Russo FP, Burra P, Senzolo M. *Minerva Gastroenterology* 2020. DOI: 10.23736/S1121-421X.20.02784-1.
68. "The impact of sarcopenia on the outcome of patients with cirrhosis with and without hepatocellular carcinoma who undergo liver transplantation". D'Arcangelo F*, **Zanetto A***, Aliberti C, Shalaby S, Pellone M, Sciarrone S, Becchetti C, Ferrarese A, Gambato M, Russo FP, Germani G, Senzolo M,

- Vitale A, Cillo U, Burra P (***equally contributed and joint first authors**). Hepatoma Research 2020. DOI: 10.20517/2394-5079.2020.109.
69. "Hepatic benefits of HCV cure: don't forget coagulation!" **Zanetto A**, Simioni P, Russo FP. Journal of Hepatology 2020. DOI: 10.1016/j.jhep.2020.10.031.
 70. "Reduced clot stability by TEG as a potential indication of procedure-related bleeding in decompensated cirrhosis". **Zanetto A**, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Hepatology communications 2020. DOI: 10.1002/hep4.1641.
 71. "Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease". Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, **Zanetto A**, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HEPATOLOGY 2020. DOI: 10.1002/hep.31462.
 72. "Acute kidney injury is associated with both hypocoagulable and hypercoagulable features in decompensated cirrhosis". **Zanetto A**, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, Wilson FP, Senzolo M, Gavasso S, Bulato C, Simioni P, Garcia-Tsao G. HEPATOLOGY 2020. DOI: 10.1002/hep.31443.
 73. "Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis". Shalaby S, Simioni P, Campello E, Spiezia L, Gavasso S, Bizzaro D, Cardin R, D'Amico F, Gringeri E, Cillo U, Barbiero G, Battistel M, **Zanetto A**, Ruzzarin A, Burra P, Senzolo M. Thrombosis and Hemostasis 2020. DOI: 10.1055/s-0040-1713169.
 74. "Influence of donor and recipient gender on liver transplantation outcomes in Europe". Germani G, Zeni N, **Zanetto A**, Adam R, Karam V, Belli LS, O'Grady J, Mirza D, Klempnauer J, Cherqui D, Pratschke J, Jamieson N, Salizzoni M, Hidalgo E, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FSJ, Villa E, Burra P; European Liver, Intestine Transplant Association (ELITA). Liver International 2020. DOI: 10.1111/liv.14510.
 75. "Some answers and more questions about portal vein thrombosis in patients with decompensated cirrhosis". **Zanetto A**, Garcia-Tsao G. Clinical Gastroenterology and Hepatology 2020. DOI: 10.1016/j.cgh.2020.04.004.
 76. "Endoscopic radiofrequency ablation for the treatment of severe Gastric Antral Vascular Ectasia in patients with cirrhosis". Senzolo M*, Realdon S*, **Zanetto A**, Simoncin B, Schepis F, Caronna S, Saracco GM, De Angelis CG, Debernardi Venon W (***equally contributed and joint first authors**). European Journal of Gastroenterology and Hepatology 2020. DOI: 10.1097/MEG.000000000000188.
 77. "Perioperative management of anti-thrombotic treatment". **Zanetto A***, Senzolo M*, Blasi A (***equally contributed and joint first authors**). Best Practice & Research Clinical Anaesthesiology 2019. DOI: 10.1016/j.bpa.2020.01.003.
 78. "Hepatitis C eradication with direct acting antivirals improves insulin resistance". Russo FP*, **Zanetto A***, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A (***equally contributed and joint first authors**). Journal of viral hepatitis 2019. DOI: 10.1111/jvh.13215.
 79. "Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct acting antivirals". Campello E, Radu CM, **Zanetto A**, Bulato C, Shalaby S, Spiezia L, Franceschet E, Burra P, Russo FP, Simioni P Liver International 2019. DOI: 10.1111/liv.14234.
 80. "Management of acute variceal haemorrhage". **Zanetto A** & Garcia-Tsao G, F1000Res. 2019. DOI: 10.12688/f1000research.18807.1.
 81. "Milestones in the discovery of Budd-Chiari syndrome". **Zanetto A**, Pellone M, Senzolo M. Liver International 2019. DOI: 10.1111/liv.14088.
 82. "Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma". **Zanetto A***, Campello E*, Spiezia L, Burra P, Simioni P, Russo FP (***equally contributed and joint first authors**). Cancers 2018. DOI: 10.3390/cancers10110450.

83. “Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C virus-related liver cirrhosis: fact or fiction”. **Zanetto A***, Shalaby S*, Ferrarese A, Becchetti C, Salvatore SS, Germani G, Senzolo M, Gambato M, Russo FP, Burra P (***equally contributed and joint first authors**). Hepatoma Research 2018. DOI: 10.20517/2394-5079.2018.102.
84. “Hepatitis C virus related cirrhosis as indication to liver transplantation since the introduction of direct-acting antivirals: a single-center study”. Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, **Zanetto A**, Shalaby S, Cillo U, Zanusi G, Angeli P, Burra P. World journal of Gastroenterology 2018. DOI: 10.3748/wjg.v24.i38.4403.
85. “Mortality in liver transplant recipients with portal vein thrombosis – an updated meta-analysis”. **Zanetto A**, Rodriguez-Castro KI, Germani G, Ferrarese A, Cillo U, Burra P, Senzolo M. Transplant International 2018. DOI: 10.1111/tri.13353.
86. “Management of bacterial infection in the liver transplant candidate”. Ferrarese A, **Zanetto A**, Becchetti C, Sciarrone SS, Shalaby S, Germani G, Gambato M, Russo FP, Burra P, Senzolo M. World Journal of Hepatology 2018. DOI: 10.4254/wjh.v10.i2.222.
87. “Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals”. Russo FP*, **Zanetto A***, Campello E, Bulato C, Shalaby S, Spiezia L, Gavasso S, Franceschet E, Radu C, Senzolo M, Burra P, Lisman T, Simioni P (***equally contributed and joint first authors**). Liver International 2018. DOI: 10.1111/liv.13873.
88. “Organ preservation in liver transplantation”. Burra P, **Zanetto A**, Russo FP, Germani G. Seminars in Liver Disease 2018. DOI: 10.1055/s-0038-1666840.
89. “Hemodynamic Evaluation of Nonselective β -Blockers in Patients with Cirrhosis and Refractory Ascites”. Ferrarese A, Tikhonoff V, Casiglia E, Angeli P, Fasolato S, Faggian D, **Zanetto A**, Germani G, Russo FP, Burra P, Senzolo M. Gastroenterology Research Practice 2018. DOI: 10.1155/2018/4098210.
90. “Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma”. Burra P, **Zanetto A**, Germani G. Cancers 2018. DOI: 10.3390/cancers10020046.
91. “Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study”. Volpato S, Montagnese S, **Zanetto A**, Turco M, De Rui M, Ferrarese A, Amodio P, Germani G, Senzolo M, Gambato M, Russo FP, Burra P. BMJ Open Gastroenterology 2017. DOI: 10.1136/bmjgast-2017-000183.
92. “Long-term care of transplant recipients: de novo neoplasms after liver transplantation”. Burra P, Shalaby S, **Zanetto A**. Current Opinion Organ Transplantation 2018. DOI: 10.1097/MOT.0000000000000499.
93. “Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents”. Schiavinato A*, **Zanetto A***, Pantano G, Tosato F, Nabergoj M, Fogar P, Piva E, Gambato M, Franceschet E, Floreani A, Farinati F, Burra P, Russo FP, Plebani M (***equally contributed and joint first authors**). Journal of Viral Hepatitis 2017. DOI: 10.1111/jvh.12746.
94. “Acute alcoholic hepatitis and liver transplantation: Waiting for Godot”. Toniutto P, **Zanetto A**, Ferrarese A, Burra P. Liver International 2017. DOI: 10.1111/liv.13461.
95. “Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network”. Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammarino A, Raimondo G, Filomia R, Coppola C, Amoroso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, **Zanetto A**, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG PLoS One. 2017. DOI: 10.1371/journal.pone.0185728.

96. "DAA in patients with Hepatocellular carcinoma before Liver Transplantation: are we sure is still an open issue?" Shalaby S, **Zanetto A**, Vitale A, Gambato M, Cillo U, Farinati F, Burra P, Russo FP. Liver Transplantation 2017. DOI: 10.1002/lt.24956.
97. "Hepatitis B and liver transplantation". Ferrarese A, **Zanetto A**, Russo FP. Minerva Gastroenterology 2017. DOI: 10.23736/S1121-421X.17.02453-9.
98. "Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service". Ferrarese A, Germani G, Lazzaro S, Cananzi M, Russo FP, Senzolo M, Gambato M, **Zanetto A**, Cillo U, Gringeri E, Perilongo G, Burra P. Liver International 2017. DOI: 10.1111/liv.13655.
99. "Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals". **Zanetto A***, Shalaby S*, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Ruggie M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP (***equally contributed and joint first authors**). Liver Transplantation 2017. DOI: 10.1002/lt.24790.
100. "Extending transplantation criteria for hepatocellular carcinoma". Burra P, **Zanetto A**, Gambato M. Lancet Gastroenterology and Hepatology 2017. DOI: 10.1016/S2468-1253(17)30143-7.
101. "Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation" Burra P, **Zanetto A**. Transplant International 2017. DOI: 10.1111/tri.12917.
102. "Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma" **Zanetto A***, Senzolo M*, Vitale A, Cillo U, Radu C, Sartorello F, Spiezia L, Campello E, Rodriguez-Castro K, Ferrarese A, Farinati F, Burra P, Simioni P (***equally contributed and joint first authors**). Digestive and Liver Disease 2017. DOI: 10.1016/j.dld.2016.12.019.
103. "Real-life data on potential drug-drug interactions in patients with chronic Hepatitis C viral infection undergoing antiviral therapy with Interferon-free DAAs in the PITER Cohort Study" Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Denis D, Russo FP, **Zanetto A**, Rumi MG, Brancaccio G, Danieli E, Weimer LE, Quaranta MG, Vella S, Puoti M. PLoS One 2017. DOI: 10.1371/journal.pone.0172159.
104. "Current challenges and future directions for liver transplantation". Toniutto P, **Zanetto A**, Ferrarese A, Burra P. Liver International 2017. DOI: 10.1111/liv.13255.
105. "Therapeutic approaches for portal biliopathy: a systematic review". Franceschet I, **Zanetto A**, Ferrarese A, Burra P, Senzolo M. World Journal of Gastroenterology 2016. DOI: 10.3748/wjg.v22.i45.9909.
106. "Rethinking the role of non-selective beta-blockers in patients with cirrhosis and portal hypertension". Ferrarese A, **Zanetto A**, Germani G, Burra P, Senzolo M. World Journal of Hepatology 2016. DOI: 10.4254/wjh.v8.i24.1012.
107. "New perspectives on treatment of hepatitis B before and after liver transplantation". **Zanetto A**, Ferrarese A, Bortoluzzi I, Burra P, Russo FP. Annals of Transplantation 2016. DOI: 10.12659/aot.900216.
108. "Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis". Campello E, **Zanetto A**, Spiezia L, Radu CM, Gavasso S, Ferrarese A, Farinati F, Senzolo M, Simioni P. Thrombosis Research 2016. DOI: 10.1016/j.thromres.2016.05.021.
109. "Liver transplantation for viral hepatitis in 2015". Ferrarese A*, **Zanetto A***, Gambato M, Bortoluzzi I, Naadal E, Germani G, Senzolo M, Burra P, Russo FP (***equally contributed and joint first authors**). World journal of Gastroenterology 2016. DOI: 10.3748/wjg.v22.i4.1570.

110. "Timing for treatment of HCV recurrence after liver transplantation: the earlier the better". Russo FP, **Zanetto A**, Burra P. *Transplant International* 2016. DOI: 10.1111/tri.12739.
111. "Hepatitis C virus and liver transplantation: where do we stand?". Burra P, De Martin E, **Zanetto A**, Senzolo M, Russo FP, Zanus G, Faggioli S. *Transplant International* 2016. DOI: 10.1111/tri.12642.
112. "Recent advances in understanding and managing liver transplantation". Russo FP, Ferrarese A, **Zanetto A**. *F1000Research* 2016. DOI: 10.12688/f1000research.8768.1.
113. "Orthotopic Liver Transplantation in alcoholic liver disease patients". Germani G, **Zanetto A**, Ferrarese A, Russo FP, Senzolo M, Burra P. *Reviews on recent clinical trials* 2016. DOI: 10.2174/1574887111666160815102228.
114. "HCC criteria for liver transplantation: controversies". Burra P, **Zanetto A**, Kryssia-Isabel Rodriguez Castro. *Liver Transplantation* 2015. DOI: 10.1002/lt.24221.
115. "Markers of acute rejection and graft acceptance in liver transplantation". Germani G, Rodriguez-Castro KI, Russo FP, Senzolo M, **Zanetto A**, Ferrarese A, Burra P. *World J Gastroenterology* 2015. DOI: 10.3748/wjg.v21.i4.1061.
116. "No evidence for increased platelet activation in patients with hepatitis B- or C- related cirrhosis and hepatocellular carcinoma". Alkozai EM, Porte RJ, Adelmeijer J, **Zanetto A**, Simioni P, Senzolo M, Lisman T. *Thrombosis Research* 2015. DOI: 10.1016/j.thromres.2014.11.016.
117. "Assessment of Bleeding Risk in Patients with Cirrhosis". **Zanetto A**, Senzolo M, Ferrarese A, Simioni P, Burra P, Rodriguez-Castro KI. *Curr Hepatology Rep* 2015. DOI: 10.1007/s11901-015-0250-1.
118. "Levels of angiogenic protein in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma". Alkozai EM, Porte RJ, Adelmeijer J, **Zanetto A**, Simioni P, Senzolo M, Lisman T. *Platelets*. 2014. DOI: 10.3109/09537104.2014.961415.
119. "Hepatitis C virus infection in end-stage renal disease and kidney transplantation". Burra P, Rodríguez-Castro KI, Marchini F, Bonfante L, Furian L, Ferrarese A, **Zanetto A**, Germani G, Russo FP, Senzolo M. *Transplant International* 2014. DOI: 10.1111/tri.12360.

Full papers published as member of the working group:

1. "Young GI Angle: The young perspective of the UEG White Book 2 by the Friends of the UEG Young Talent Group". Simsek C, Dugic A, Domislovic V, Te Groen M, Hadeifi A, Kravchuk S, Porcari S, Sochnieva A, Sousa P, Acedo P; **UEG Friends of Young Talent Group**. *United European Gastroenterol J*. 2023. DOI: 10.1002/ueg2.12478.
2. "Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference". Pollok JM, Tinguely P, Berenguer M, Niemann C, raptis DA, Spiro M, on behalf of the **ERAS4OLT.org collaborative**. *THE LANCET Gastroenterology & Hepatology* 2023. DOI: 10.1016/S2468-1253(22)00268-0.
3. "The application of artificial intelligence in hepatology: a systematic review". Balsano C, Alisi A, Brunetto MR, Invernizzi P, Burra P, Piscaglia F and **collaborators** Alvaro D, Bonino F, Carbone M, Faita F, Gerussi A, Persico M, Santini SJ, Zanetto A. *Digestive and Liver Disease* 2021. DOI: 10.1016/j.dld.2021.06.011.
4. "Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: a real-life evaluation of the PITER cohort". Quarante MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Bilotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ileuzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA and **PITER collaborative group**. *Digestive and Liver Disease* 2021. DOI: 10.1016/j.dld.2021.03.020.

5. “Economic consequences of investigating in anti-HCV antiviral treatment from the Italian NHS perspective” Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; **PITER Collaborating group**. *Pharmacoeconomics* 2018. DOI: 10.1007/s40273-018-0733-3.
6. “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV”. Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F, Bristot L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, Villa E; PITER framework investigators; **PITER Investigators** – *Journal of Hepatology* 2017. DOI: 10.1016/j.jhep.2017.08.019.
7. “AISF Position Paper Common issues in the management of patients in the waiting list and after liver transplantation: HCV, HBV, alcoholic liver disease, immunosuppression”. Burra P, Belli LS, Ginanni Corradini S, Volpes R, Marzioni M, Giannini E, Toniutto P *Digestive and Liver Disease* 2017 (“**expert collaborator and part of the working groups**”). DOI: 10.1016/j.dld.2016.12.027.

Book chapters:

1. “Liver transplantation – the recipient, specific indications: alcohol use” Burra P, Bizzaro D, **Zanetto A**, Senzolo M, Germani G, “Living donor liver transplantation”, Volume 2, second edition. Volume 2 ISBN: 978-0-44323574-0.
2. “HVPG as a Gold Standard: Accuracy Is Essential” Garcia-Pagàn JC, Schepis F, Gaba RC, Zanetto A, Perez-Campuzano V, Haskal Z, Ferral H. in de Franchis R “Portal Hypertension VII – Proceedings of the 7th Baveno Consensus Workshop: Personalized Care in Portal Hypertension”, Springer Nature Switzerland 2022, <https://doi.org/10.1007/978-3-031-08552-9>
3. “Anticoagulation in splanchnic vein thrombosis with and without underlying liver disease” Senzolo M, **Zanetto A**, in de Franchis R “Portal Hypertension VII – Proceedings of the 7th Baveno Consensus Workshop: Personalized Care in Portal Hypertension”, Springer Nature Switzerland 2022, <https://doi.org/10.1007/978-3-031-08552-9>.
4. “Recurrence of primary liver disease” Russo FP, **Zanetto A** in Burra P “Textbook of liver transplantation: a multidisciplinary approach”, Springer Nature Switzerland 2022 (in press).
5. “Gastroesophageal bleeding management” **Zanetto A**, Garcia-Tsao G in Rahimi “The critically ill cirrhotic patient”, Springer, 2020, https://doi.org/10.1007/978-3-030-24490-3_4.
6. “History of Budd Chiari Syndrome” Pellone M, **Zanetto A**, Senzolo M in Xingshun QI “Budd-Chiari Syndrome”, Springer 2019, https://doi.org/10.1007/978-981-32-9232-1_1.
7. “Management of thrombosis in liver transplant candidate” **Zanetto A**, Senzolo M in Bezinover/Saner “Critical care for potential liver transplant candidate”, Springer, 2018, https://doi.org/10.1007/978-3-319-92934-7_8.

2. Summary of conferences and seminars

Invited lectures at national and international meetings: 32.

Invited moderations at national and international meetings: 3.

Oral abstracts at national and international meetings: 23.

Conference and seminars national and international attended: 121

Invited lectures at national and international meetings:

1. “Portal hypertension lab”, AISF Annual Meeting 2024 (Roma, 15-16/03/2024 - invited).
2. “«Prendi e porta a casa»: come andare all'estero e proseguire le collaborazioni scientifiche”, CAMPUS Comitato UNIGASTRO per la Didattica in COLMAD-SIGE” (San Sepolcro, 7-9/03/24 - invited).
3. “What university hepatologists should know about hemostasis in patients with cirrhosis”, monthly scientific meeting (University of Rennes, 13/02/24).

4. “Grand Round on vascular liver disease”, XXXV Symposium Associazione Roberto Farini ONLUS per la Ricerca Gastroenterologica. (Padova, 26-27/01/2024).
5. “TIPS for refractory hydrothorax: is it a different patient?”, Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Radiological Interventions for the Treatment of Portal Hypertension, 12/12/2023.
6. “L’ipertensione portale. Come misurarla e conseguenze cliniche”, Master interuniversitario di II livello in Medicina dei Trapianti ed Epatologia Avanzata, 10/11/2023.
7. “Sarcopenia in liver cirrhosis: pathogenesis and prognostic role”, Campus AGGEI 2023 25/11/2023
8. “Coagulopathy in cirrhosis: recent evolution and open questions”, Ground Round Boston Medical Center, 16/11/2023.
9. “Differenze di genere nelle malattie vascolari epatiche”, 46° Congresso Nazionale della Società Italiana dei Trapianti d’Organo e di Tessuti, 8/10/2023.
10. “Ruolo prognostico delle alterazioni emostatiche nei pazienti con cirrosi epatica”, DiSCOG Il futuro della ricerca scientifica, 14/09/2023
11. “La coagulopatia del cirrotico”, Liver Preceptorship II Edition, Improving Outcomes in Chronic Liver Disease, 5/7/23.
12. “The frail sarcopenic candidate: how to assess the eligibility for liver transplantation and predict the outcome”, AISF Annual Meeting 16/03/2023.
13. “Emostasi nel cirrotico: nuove evidenze dalla teoria alla pratica clinica”, Seminari Scuola di Specializzazione Malattie Apparato Digerente Sapienza Università di Roma, 03/03/23.
14. “Malattie vascolari e trombosi – Webinar AISF Gender in Hepatology”, 22/02/23.
15. “Valutazione della body composition nel paziente cirrotico” Master interuniversitario di II livello in Medicina dei Trapianti ed Epatologia Avanzata, 10/11/2022.
16. “Raccomandazioni e LG e ipertensione portale” 2° Gastro Up To-Date; Focus: HCC e ipertensione portale, cosa sta cambiando – 20/10/2022 .
17. “Difficult to treat patients with cirrhosis” Summer School – Advanced Liver Disease and Beyond – 2022.
18. “Coagulopathy in patients with chronic liver disease: from bench to bedside” Summer School - Precision Medicine 2022: Improving treatments through defining mechanism – 14/09/2022.
19. “NSBBs in patients with cirrhosis: indications and contraindications” EASL School of Hepatology Clinical Problems in the Management of Cirrhosis and Portal Hypertension-Related Complications – 17/06/2022
20. “Presentazione di uno dei tre migliori lavori scientifici del Dipartimento all’evento Storia di un’eccellenza – dal teatro anatomico ad DiSCOG, tra chirurgia, clinica e ricerca” – 10/05/2022.
21. “Patogenesi e valore prognostico della sarcopenia nel paziente cirrotico” – Post graduate course FISMAD-AISF – 11/05/2022.
22. “Dalla trasfusione piastrinica ai TPO: si, no...forse” – Masterclass AISF, Gestione clinica e strumentale dell’ipertensione portale – 25/11/2021.
23. “HCC, cirrhosis, and hemostasis: where do we stand?” – Masterclass AISF, Gestione multidisciplinare del paziente con epatocarcinoma e colangiocarcinoma – 19/11/2021.
24. “La trombocitopenia nel paziente affetto da malattia cronica di fegato e presentazione caso clinico” – Webinar: Malattia epatica avanzata con trombocitopenia: un nuovo approccio alla gestione delle procedure invasive – 22/10/2021.
25. “Caso clinico interattivo II” – Webinar AISF – 15/10/2021.
26. “Caratterizzazione e risvolti terapeutici della biliopatia portale” – 27° congresso nazionale delle vie digestive FISMAD – 24/09/2021.
27. “Dalla trasfusione piastrinica alla TPO: si, no...forse” - Webinar AISF – 22/09/2021.
28. “Definition of sarcopenia and frailty in liver transplant recipients” – 20th ESOT conference – 01/09/2021.

29. “Portal vein thrombosis in patients with cirrhosis: which anticoagulant therapy?” – webinar DOACs and venous thromboembolism – 22/06/2021.
30. “A Challenging Liver Transplantation for Decompensated Cirrhosis after Recovery from SARS-CoV-2 Infection” – Webinar ILTS – 12/04/2021.
31. “My most difficult clinical case” - hepatology – Liver transplantation today: the interaction between hub and spoke centers EPAday virtual meeting – 2020.
32. “Clinical case about HCV recurrence after liver transplantation” – Liver Transplantation: the interaction between hub and spoke centers: from clinical practice to scientific evidence – 2016.

Invited moderations at national and international meetings.

1. Paris Portal Vein Thrombosis Meeting, Paris, 29-30/11/2022.
2. Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Radiological Interventions for the Treatment of Portal Hypertension, Padova 12/12/2023.
3. XXXV Symposium Associazione Roberto Farini ONLUS per la Ricerca Gastroenterologica, Padova 26-27/01/2024 (co-organizer of the meeting).

Oral abstracts at national and international meetings:

1. “CiThroModel improves the prediction of venous thromboembolism in hospitalized patients with cirrhosis” – AIFS Annual Meeting 2024 (selected).
2. “Increased level of presepsin indicates a higher risk of ACLF in patients with acutely decompensated cirrhosis” – moderated poster EASL 2023.
3. “Increased level of presepsin indicates a higher risk of ACLF in patients with acutely decompensated cirrhosis” – AIFS Annual Meeting 2023.
4. “Global hemostatic profiling in patients with decompensated cirrhosis with bacterial infections shows sustained impairment of platelet aggregation and reduced level of natural anticoagulants” – UEG week 2022.
5. “Increased platelet aggregation in decompensated cirrhosis indicates higher risks of further decompensation and liver-related mortality” – AIFS Annual Meeting 2022.
6. “Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure” – EASL Conference on Bleeding, Thrombosis, and Vascular Liver Diseases – 2021.
7. “Acute kidney injury is associated with reversible platelet dysfunction in patients with decompensated cirrhosis” – AIFS Annual Meeting 2020 (meeting cancelled due to COVID19).
8. “NUCs: hics et nunc?” AASLD & EASL Joint Masterclass – 2018.
9. “Hepatocellular carcinoma recurrence in cirrhotic patients after sustained virological response” – XXIX Roberto Farini Symposium – 2018.
10. “Reversal of hypercoagulability in patients with HCV-related liver cirrhosis after treatment with DAAs: a cohort study with 1-year follow-up” – Liver gymnasium – 2017.
11. “De novo autoimmune hepatitis recurrence after IFN-free antiviral therapy for hepatitis C after liver transplantation” – ILTS International meeting (post-graduate course) – 2017.
12. “Aged, anti-HBcore+, anti-HCV+ graft: can we use it?” – ILTS International Meeting – 2017.
13. “Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy” – AIFS Annual Meeting – 2017.
14. “Can treatment be discontinued in HBV patients? PRO (favouring stop of treatment)” – EASL Masterclass 2016.
15. “Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma” – ILTS International Congress – 2016.
16. “Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma” – EASL International Liver Congress – 2016.

17. “Outcomes of IFN-free antiviral therapy for HCV in liver transplant setting: single center experience” – XXVII Roberto Farini Symposium – 2016.
18. “Treating the HCV decompensated cirrhotic patients: before or after liver transplantation? CONS (favouring post-transplant therapy)” – EASL Masterclass – 2015.
19. “Liver fibrosis in patients with HCV recurrence after liver transplantation: early protective role of N-Acetylcysteine. Long Terms (5 years) results of a randomized controlled trial” - XXVII national conference of the Italian Society of Organ Transplantation – 2014.
20. “Prospective evaluation of the correlation between hemostatic alterations and incidence of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma” – EASL International Liver Congress 2014.
21. “The impact of De Novo Autoimmune Hepatitis in patients with HCV recurrence after liver transplantation” - XXVII national conference of the Italian Society of Organ Transplantation – 2013.
22. “Liver transplantation for multifocal hepatocellular carcinoma in non-cirrhotic portal hypertension” - XXVII national conference of the Italian Society of Organ Transplantation – 2013.
23. “Effect of portal vein thrombosis on survival after liver transplantation: a metanalysis” – Conference organized by the Society for the Quality in Organ Transplantation: Building a better world for our transplant patients – 2013.

National and international conferences and seminars attended:

1. 56 Annual Meeting of the Italian Association for the Study of the Liver (Rome, 16-16/03/2024).
2. CAMPUS Comitato UNIGASTRO per la Didattica in COLMAD-SIGE” (San Sepolcro, 7-9/03/24)
3. XXXV Symposium Associazione Roberto Farini ONLUS per la Ricerca Gastroenterologica. (Padova, 26-27/01/2024).
4. Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Radiological Interventions for the Treatment of Portal Hypertension (Padova, 12/12/2023)
5. Campus AGGEI Connecting, Innovating, Evolving together 2023 (Rome, 25/11/2023)
6. 46° Congresso Nazionale della Società Italiana dei Trapianti d’Organo e di Tessuti (Rome, 8/10/2023)
7. AISF Monothematic conference 2023: Liver oncology: from basic science to liver transplantation (Padova, 28-29/09/2023)
8. Liver Preceptorship II Edition, Improving Outcomes in Chronic Liver Disease (Padova, 5/7/23)
9. European Association for the Study of the Liver the International Liver Congress 2022 (Vienna, 21-24/06/2023).
10. 29° congresso Nazionale delle malattie digestive FISMAD (Rome, 29/03-01/04/23).
11. 55 Annual Meeting of the Italian Association for the Study of the Liver (Rome, 16-17/03/2023).
12. Webinar AISF: Gender in Hepatology (22/02/23).
13. Pre-meeting and XXXIV symposium Associazione Roberto Farini Onlus per la ricerca in Gastroenterologia (Padova, 26-20/01/2023).
14. Paris Portal Vein Thrombosis Meeting, (Paris, 29-30/11/2022).
15. 2° Gastro Up To-Date; Focus: HCC e ipertensione portale, cosa sta cambiando (Vicenza, 20/10/2022).
16. UEG week 2022 (Vienna, 8-11/10/2022).
17. Summer School - Precision Medicine 2022: Improving treatments through defining mechanism (Oxford, 14-16/09/2022).
18. European Association for the Study of the Liver International Liver Congress 2022 (London, 22-26/06/2022).
19. 54th Annual Meeting of the Italian Association for the Study of the Liver (Rome, 24-25/03/2022).
20. Pre-meeting and XXXIII symposium Associazione Roberto Farini Onlus per la ricerca in Gastroenterologia (10-12/03/2022).
21. International Liver Transplant Society (ILTS) Virtual Consensus Conference 2022 (28-29/02/2022)

22. Masterclass AISF 2021, Gestione clinica e strumentale dell'ipertensione portale (Modena, 24-26/11/2021).
23. Masterclass AISF 2021, Gestione multidisciplinare del paziente con epatocarcinoma e colangiocarcinoma, (Padova, 17-19/11/2021).
24. The Liver Meeting Digital Experience - American Association for the Study of the Liver (12-15/11/2021).
25. Webinar: Baveno VII – Consensus Workshop Personalized Care in Portal Hypertension (27-31/10/2021).
26. Webinar: malattia epatica avanzata con trombocitopenia: un nuovo approccio alle procedure invasive (22/10/2021).
27. Webinar: The 2° PITER meeting (15/10/2021).
28. Webinar AISF: “Clinical management of PSVD-Porto-Sinusoidal Vascular Liver Disease” (15/10/2021).
29. European Association for the Study of the Liver Conference on Bleeding, Thrombosis and Vascular Liver Diseases 2021 (Geneve, 6-9/10/2021).
30. UEG Week Virtual 2021 (03-05/10/2021).
31. Il trapianto di fegato. Interazione tra il centro trapianti e le Unità di Epatologia-Gastroenterologia. Gestione del paziente con malattie epatiche oncologiche e virali. V edizione (Padova, 1/10/2021).
32. Webinar 27° congresso Nazionale delle Malattie Digestive (FISMAD) (22-25/09/2021).
33. Webinar AISF: La gestione della piastrinopenia severa nel paziente cirrotico candidato a procedure invasive (22/09/21).
34. 20th Congress of the European Society for Organ Transplantation ESOT (Milano, 29/08-01/09/21).
35. Webinar: “DOACs and venous thromboembolism” (22/06/2021).
36. “53rd Annual Meeting of the Italian Association for the Study of the Liver” Virtual meeting (3-5/03/2021).
37. EASL Digital Liver Cancer Summit 2021- European Association for the Study of the Liver (5-6/02/2021).
38. Webinar: Masterclass AISF 2020 “Gestione clinica e strumentale dell'ipertensione portale” (Modena, 11-13/11/2020).
39. The Liver Meeting 2020, Digital Experience - American Association for the Study of the Liver (13-16/11/2020).
40. Liver transplantation today – the interaction between hub and spoke centers – EPAday virtual meetings (22-27/10/2020).
41. The Digital International Liver Congress 2020 – European Association for the Study of the Liver (27-29/08/2020).
42. Annual Rosemarie Fisher Lectureship in Digestive Diseases “Escape from LaLa Land: From LA to yale and beyond” – Yale School of Medicine (28/01/2020).
43. 35th Annual Gerald Klatskin MD Memorial Lectureship in Hepatology “The liver belongs to the biliary tree” – Yale School of Medicine (15/01/2020).
44. Liver Preceptorship – Improving outcome in chronic liver disease (Padova, 11-13/12/2019).
45. The Liver Meeting 2019 – American Association for the Study of the Liver (Boston, 8-12/11/2019).
46. Gastrointestinal Core Curriculum Lecture Series – Yale School of Medicine (2019-2020).
47. Digestive Diseases Research Seminars – Yale School of Medicine (2019-2020).
48. Summer school “Translational and Personalized Medicine: from bench to the bedside”, joint program between Padova and Oxford Universities (Padova, 17-21/06/2019).
49. Joint meeting AISF-ELITA: “Hepatologist in a liver transplant program (HLTP) course” (Roma, 13-14/06/2019).
50. Yale Liver Cancer Symposium 2019: The Changing Landscape of Hepatocellular Carcinoma (HCC) Management – Yale School of Medicine (1/3/2019).

51. Annual Samuel D. Kushlan, MD, Visiting Lectureship in Gastroenterology “Etiopathogenesis of Functional Dyspepsia – Are You Missing the Diagnosis and What to Do” – Yale School of Medicine (20/02/2019).
52. Inaugural Dr. Rosemarie Fisher Lectureship in Digestive Diseases “For bariatric surgery to Bariatric Endoscopy: New approach in obesity” – Yale School of Medicine (22/01/2019).
53. 33rd Annual Gerald Klatskin MD Memorial Lectureship in Hepatology “Molecular and cellular drivers of innate immune activation in steatohepatitis” – Yale School of Medicine (16/01/2019).
54. Gastrointestinal Core Curriculum Lecture Series – Yale School of Medicine (2018-2019).
55. Digestive Diseases Research Seminars – Yale School of Medicine (2018-2019).
56. Yale Liver Update 2018 – Yale School of Medicine (14/12/2018).
57. Joint Masterclass - European Association for the Study & American Association for the Study of the Liver (Orlando, 29/11-01/12/2018).
58. Liver Center retreat – Yale School of Medicine (17/11/2018).
59. The Liver Meeting 2018 – American Association for the Study of the Liver (San Francisco, 9-13/11/2018).
60. Il trapianto di fegato – Interazione tra il centro trapianti e le Unità di Epatologia-Gastroenterologia (15/06/2018).
61. 51^o Pre- Meeting e Annual Meeting Italian Association for the Study of the Liver (Roma, 21-23/02/2018).
62. NASH Consensus Conference – International Liver Transplantation Society (Venezia, 15/02/2018).
63. XXIX Symposium Associazione Roberto Farini Onlus (Padova, 1-3/02/2018).
64. VIII Corso residenziale Avanzato in Epatologia (Padova, 16/11/2017).
65. European Association for the Study of the Liver Clinical School of Hepatology Course: Controversies in End-Stage Liver Disease (Madrid, 24-25/11/2017).
66. XIII Update in Gastroenterologia (Udine, 9/11/2017).
67. Coagulation in Liver Disease 2017: “Refining New Concepts: Bridges & Gaps” (Roma, 6-7/10/2017).
68. Liver Transplantation: the interaction between hub and spoke centers: from clinical practice to scientific evidence (Padova, 16/06/2017).
69. Annual Reunion of Northern Italian Transplant Program (Milano, 29/05/2017).
70. International Liver Transplant Society 23rd Annual International Congress (Prague, 24-27/5/2017).
71. 3rd Expert Meeting of Transplant Hepatologist - Italian Association for the Study of Liver (Mondello, 12-13/05/2017).
72. International Liver Congress 2017 - European Association for the Study of the Liver (Amsterdam, 19-23/04/2017).
73. HCC Meeting - European Association for the Study of the Liver (Geneve, 2-5/02/2017).
74. 50^o Pre- Meeting e Annual Meeting Italian Association for the Study of the Liver (Roma, 22-24/02/2017).
75. XXVIII Symposium Associazione Roberto Farini Onlus (Padova, 26-28/01/2017).
76. Liver Gymnasium 4 (Padova, 29/11/2017).
77. Masterclass European Association for the Study of the Liver (Frankfurt, 1-3/12/2016).
78. 50^o Congress of the Italian Society for Organ Transplantation (Roma, 26-28/10/2016).
79. Hepatologist in a liver transplant program - European Society for Organ Transplantation (Rotterdam, 21-23/10/2016).
80. European Association for the Study of the Liver Special Conference “New perspective in HCV virus infection: a roadmap for cure (Paris, 23-24/09/2016).
81. Liver Transplantation: the interaction between hub and spoke centers (Padova, 17/06/2016).
82. Summer School United European Gastroenterology (Prague, 2-5/06/2016).

83. Liver transplantation in HCV positive recipients. Consensus conference and guidelines development: management of HCV in transplant recipients - International Liver Transplantation Society (Rosemont, 4-5/05/2016).
84. International Liver Transplant Society 22nd Annual International Congress (Seoul, 4-7/05/2016).
85. The International Liver Congress 2016 - European Association for the Study of the Liver (Barcelona, 13-17/03/2016).
86. 22^o National Congress of the Italian Association for the Study of Gastrointestinal Diseases (Napoli, 24-27/02/2016).
87. 49th Pre- Meeting e Annual Meeting Italian Association for the Study of Liver (Roma, 17-19/02/2016).
88. XXVII Symposium Associazione Roberto Farini Onlus (Padova, 28-30/01/2016).
89. Medical Education in HBV-HCV (Padova, 14/01/2016).
90. Masterclass - European Association for the Study of the Liver (Mezzana Bavigli, 3-5/12/2015).
91. EXHPO: expertise in Hepatitis, Perspectives and Opportunities (Firenze, 7-8/10/2015).
92. 2nd Expert Meeting of Transplant Hepatologist - Italian Association for the Study of Liver (Mondello, 4-5/10/2015).
93. European Association for the Study of the Liver Special Conference: Addressing End-Stage Liver Disease, a multifaceted challenge (Glasgow, 25-27/09/2015).
94. European Association for the Study of the Liver Clinical School of Hepatology: liver cirrhosis and its complications (Moscow, 5-6/06/2015).
95. HCV: new therapeutic opportunities (Bologna, 18/06/02015).
96. Liver transplantation in HCV positive recipients: facing a new era (Milano, 6/03/2015).
97. The International Liver Congress 2015 - European Association for the Study of the Liver (Vienna, 22-26/04/2015).
98. 48th Italian Association for the Study of the Liver Annual Meeting (Roma, 20-21/02/2015).
99. XXVI Symposium Roberto Farini Association (Padova, 31/01-1/02/2015).
100. Hepatitis Journey post-AASLD (Ospedaletto di Pescantina, 19/12/2015).
101. Focus on patients with HBV and HCV chronic viral hepatitis (Vicenza, 21/11/2014).
102. XXXVIII Organ Transplant Italian Society National Meeting (Siena, 24-26/09/2014).
103. International Liver Congress 2014 – European Association for the Study of the Liver (London, 9-13/04/2014).
104. 20^o National Congress of Digestive Disease FISMAD (Italian Association for the Study of Gastrointestinal disease (Napoli, 19-22/03/2014).
105. Liver Gymnasium Pre-meeting and XXIII International Congress of new perspectives in hepatology (Padova, 13-14/03/2014).
106. Strategies and challenges for viral hepatitis treatments (Venezia, 6/03/2014).
107. HCC Summit - European Association for the Study of the Liver (Geneve, 15-16/02/2014).
108. 47th Italian Association for the Study of the Liver Annual Meeting (Roma, 20-21/02/2014).
109. 16th Italian Association for the Study of the Liver Pre-Meeting Course “Indications to liver transplantation and management of patients in the waiting list” (Roma, 19/02/2014).
110. XXV Symposium Roberto Farini Association (Padova, 31/01-1/02/2014).
111. Monothematic conference of Italian Association for the Study of the Liver: personalization of the cure in hepatology (Pisa, 11/11/2013).
112. XXXVII Organ Transplant Italian Society National Meeting (Bari, 24-26/10/2013).
113. 5th International Congress on Coagulopathy in Liver Disease (Padova, 27-28/09/2013).
114. Building a better world for our transplanted patients (Firenze, 8-12/04/2013).
115. XXIV Symposium Associazione Roberto Farini Association and theoretical-practical Course: Present and Future in Digestive Endoscopy (Padova, 31/01-1/02/2013).
116. Bookmarks in Hepatology – 2012 (Bologna, 10-11/12/2012).

117. L'ipertensione portale in Italia– 2012 (Milano, 26-27/10/2012).
118. Hospital program in HBV (Padova, 11/07/2012).
119. XXIII Symposium Roberto Farini Association and pre-meeting: “Evidence based medicine in Gastroenterologia ed Epatologia” (Padova, 27-28/01/2012).
120. 6th International Conference on Thrombosis and Hemostasis issue in cancer (Bergamo, 20-22/04/2012).
121. “Meeting del martedì” – Gastroenterologia, Università di Padova (2010/2011, 2011/2012; 2013/2014; 2014/2015; 2015/2016; 2016/2017; 2017/2018; 2020/2021; 2021/2022; 2022/2023; 2023/2024).

3. Summary of research funding and prizes for excellence in clinical research

Research funding: 236.198 euro.

Research prizes given by National and International Scientific Societies or Foundations: 10

Research bursary to support participation at national and international meetings: 24

Research funding

- Dotazione Ordinaria Ricerca (DOR) funded by the Department of Surgery, Oncology and Gastroenterology of Padova University (2023) for the project: “Whole blood thrombin generation in patients with cirrhosis”. Amount: 6128 euro. Role: PI.
- Progetti SID (BIRD) funded by the Department of Surgery, Oncology and Gastroenterology of Padova University (2023) for the project “Assessment of non-anticoagulant effects of heparin treatment in patients with cirrhosis”. Amount: 30.000 euro. Role: PI.
- PortoSinusoidal Vascular Disease: Risk stratification & Therapeutic Approaches funded by the Fondazione Telethon within the call “Natural History Studies addressing unmet needs in Rare Diseases by the European Joint Programme Rare Diseases). Amount: 199,980 euro. Role: PI.

Research prizes given by national and international scientific societies or foundations:

1. “Premio SIGE” for the best Italian publication 2022.
2. Best oral communication (clinical) by the Italian Association for the Study of the Liver 2023.
3. “Premio AISF” for the best Italian publication (category clinical) 2022.
4. Zegna Founders’ Scholarship (Ermenegildo Zegna Foundation) 2018.
5. “2018 Clinical and Translation Research Fellowship award” by the American Association for the Study of the Liver (AASLD) Foundation
6. Best young investigator (“North Italian Transplant”) 2017.
7. “Andrew K. Burroughs Short-term training research fellowship” by the European Association for the Study of the Liver 2016.
8. Best poster presentation (clinical) by the Italian Association for the Study of the Liver 2016.
9. Research bursary “Giulia” awarded by the ONLUS Marina Minnaja 2014.
10. “Premio AISF giovani laureati” by the Italian Association for the Study of the Liver 2013.

Research bursary to support participation at national and international meetings:

1. “Young Investigator” bursary at the “International Liver Congress” by the European Association for the Study of the Liver 2023.
2. “The Liver Meeting Travel Award” at the “The Liver Meeting” by the American Association for the Study of the Liver 2022.
3. “UEG Travel grant” at the UEG Week 2022.
4. “Young Investigator” bursary at “Conference on Bleeding, Thrombosis, and Vascular Liver Disease” by the European Association for the Study of the Liver 2021.

5. “Young Investigator” bursary at “HCC Summit” by the European Association for the Study of the Liver 2021.
6. “Young Investigator” bursary at “Masterclass” by the European Association for the Study of the Liver 2018.
7. “Young Investigator” at “School of Hepatology” by the European Association for the Study of the Liver 2015.
8. “Young Investigator” bursary at “International Liver Transplantation Society Congress” 2017.
9. “Young Investigator” bursary at “International Liver Congress” by the European Association for the Study of the Liver 2015.
10. “Young Investigator” at “HCC Summit” by the European Association for the Study of the Liver 2017.
11. “Young Investigator” at Italian Association for the Study of the Liver Annual Meeting 2017.
12. “Young Investigator” bursary at “Masterclass” by the European Association for the Study of the Liver.
13. “Young Investigator” at “Special Conference” by the European Association for the Study of the Liver 2016.
14. “Young Investigator” at “Summer School” UEG 2016.
15. “Young Investigator” at “International Liver Congress” by the European Association for the Study of the Liver 2016.
16. “Young Investigator” at Italian Association for the Study of the Liver Annual Meeting 2016.
17. “Young Investigator” at “Masterclass” by the European Association for the Study of the Liver 2015.
18. “Young Investigator” at “Special Conference” by the European Association for the Study of the Liver 2015.
19. “Young Investigator” at “School of Hepatology” by the European Association for the Study of the Liver 2015.
20. “Young Investigator” at “International Liver Congress” by the European Association for the Study of the Liver 2015.
21. “Young Investigator” at Italian Association for the Study of the Liver Annual Meeting 2015.
22. “Young Investigator” at “International Liver Congress” by the European Association for the Study of the Liver 2014.
23. “Young Investigator” bursary at “HCC Summit” by the European Association for the Study of the Liver 2014.
24. “Young Investigator” by the European Association for the Study of the Liver 2014.

4. Scientific societies

- Italian Association for the Study of the Liver (AISF) since 2011
- European Association for the Study of the Liver (EASL) since 2012
- Italian Society Gastroenterology (SIGE) since 2012
- Italian Society for Organ Transplantation (SITO) in 2013-2014
- International Liver Transplant Society (ILTS) in 2016-2017
- European Society for Organ Transplantation (ESOT) in 2016-2017
- American association for the Study of the Liver (AASLD) since 2017
- COLMAD (Collegio Nazionale Docenti Malattie Apparato Digerente) since 2022
- Member of the Friends of the Young Talent Group UEG (United European Gastroenterology) since 29/12/2021
- Member of the Young Committee SIGE since 8/04/2022
- Member of the Special Interest Group “Portal hypertension” AASLD since 01/01/2023

5. Co-PI in 10 clinical trials in gastroenterology and hepatology:

1. Randomized control trial of HCV recurrence treatment with standard therapy vs pre-induction with ribavirin followed by standard antiviral therapy (PEARL).
2. Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in hepatitis C Genotype 1 infected, Stable Liver transplant.
3. Observational Italian study for the evaluation of the renal insufficiency in liver transplanted patients (SURF).
4. Pilot Project of educational intervention to improve adherence to medical therapies in patients undergoing liver transplantation (SINGLE).
5. Impact assessment of therapy with subcutaneous immunoglobulin anti-HBV on quality of life and satisfaction of patients undergoing liver transplantation (TWINS II).
6. Use of donors with brain injuries HBsAg positive, anti-HBcore positive or anti-HCV positive according to national guidelines: improving the allocation model of the liver through the collection and evaluation of the results of organ and patient survival in the short, medium and long term.
7. Transplant ... and now sports! Effects of exercise in patients with solid organ transplantation.
8. An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin as Pre-Emptive Administration in Transplant-Recipients with Hepatitis C Virus (HCV) active infection (SOFOLT 2).
9. Viral kinetics study in HCV infected patients undergoing OLT and Sofosbuvir therapy (SOFOLT 2 Ancillary study).
10. Clinical and economic burden of CMV in kidney and other solid organ transplants (SOT) in Italy.

6. Editorial board member or reviewer for peer-reviewed scientific journals:

Editorial board member:

1. Hepatoma research (Youth Editor) (2019-ongoing)
2. Digestive Medicine Research (Editorial Board) (2019-2022)
3. United European Gastroenterology Journal (Editor in training, category: liver) (2019-2022)
4. Medicina (2023-ongoing)
5. Frontiers in cardiovascular medicine, section Thrombosis (since May 2022)
6. JHEP Reports (since January 2024)

Reviewer:

1. Digestive and Liver Disease
2. Transplant International
3. Canadian Journal of Gastroenterology and Hepatology
4. Annals of Hepatology
5. Annals of Transplantation
6. BMC gastroenterology
7. Expert Review of Anti-infective therapy
8. World Journal of Surgical Oncology
9. Hepatoma Research
10. Neoplasia
11. Clinical Transplantation
12. HEPATOLOGY
13. Transplantation
14. Medicina

15. United European Gastroenterology Journal
16. Renal failure
17. Scientific report
18. Alimentary, Pharmacology & Therapeutics
19. Liver Transplantation
20. Internal and Emergency Medicine
21. Frontiers in Cardiovascular Medicine
22. Journal of Hepatology
23. Journal of Clinical Medicine
24. Journal of Vascular and Interventional Radiology
25. Digestive and Disease Science
26. American Journal of Transplantation
27. JHEP Reports
28. Advances in Medical Sciences
29. Nephron

6. National and international research groups:

1. Piattaforma Italiana per lo studio della Terapia delle Epatiti Virali (PITER).
2. Special Interest Group “Gender in Hepatology” – Associazione Italiana per lo Studio del Fegato.
3. ERAS4OLT “Enhanced recovery for liver transplant” – in partnership with International Liver Transplantation Society and ILTS Vanguard Committee.
4. European Respiratory Society (ERS) taskforce for the “management of benign pleural effusion”; subgroup on hepatic hydrothorax.
5. European Reference Networks (ERN) – Hepatological Diseases (ERN RARE-LIVER)
6. Special Interest Group “Portal hypertension” – AASLD
7. DARE – Digital Environment for collaborative Alliances to Regenerate urban Ecosystems in middle-sized cities. Spoke 3, WP4, pilot: Bringing Medicine Digitalization into the Italian Solid Organ Transplant Network.

TEACHING ACTIVITY

- Gastroenterology, Medicine and Surgery, Padova University (academic years: 2022/2023, 2023/2024)
- Gastroenterology, bachelor’s degree course of Nursing, Padova University (academic years: 2022/2023, 2023/2024)
- “Cirrhosis, ACLF, and portal hypertension”, Gastroenterology fellowship, Padova University (academic year 2023/2024)
- Co-organizer of the Master in “Transplant Medicine and advanced hepatology” organized by Padua and Bicocca University (academic year 2023/2024)
- Medical student (Medicine and Surgery) thesis co-supervisor since 2016 (n=9)
 - Padua University (n=8):
 - Valutazione dei cambiamenti del profilo emostatico in pazienti con cirrosi HCV-correlata sottoposti a terapia con farmaci antivirali diretti (studente: Martina Tessari, 2016).
 - Impatto delle nuove terapie con antivirali ad azione diretta sullo di ipercoagulabilità nei pazienti con cirrosi epatica HCV-correlata (studente: Eugenio Marconato, 2017).

- Ripristino dei linfociti B dopo trattamento con farmaci antivirali ad azione diretta in pazienti con epatopatia HCV-correlata (studente: Francesca Barcaro, 2017).
- Microvescicole plasmatiche circolanti e rischio di trombosi nei pazienti con cirrosi trattati con antivirali ad azione diretta (studente: Daniele Fasan, 2018).
- Sarcopenia e alterata distribuzione del tessuto adiposo in pazienti con cirrosi con e senza epatocarcinoma: ruolo sull'*outcome* dopo trapianto di fegato (studente: Francesca D'Arcangelo, 2019).
- Utilizzo di test non invasivi per la stratificazione del rischio di scompenso epatico in pazienti con cirrosi HCV-correlata sottoposti a terapia antivirale con farmaci ad azione diretta (studente: Francesco Masiero, 2021).
- Valutazione delle alterazioni emostatiche in pazienti con epatite virale cronica (studente: Silvia Sturani, 2021).
- Cambiamenti a lungo termine del profilo coagulativo in pazienti con cirrosi HCV-correlata sottoposti a eradicazione virale (studente: Anna Piazza, 2021).
- University of Modena and Reggio Emilia (n=1)
 - Influenza del carcinoma epatocellulare sull'aggregazione piastrinica in pazienti cirrotici (studente: Marco Scopettuolo, 2021).
- Medical student (Medicine and Surgery) thesis co-examiner (n=2)
 - Utilizzo del test rapido salivare per lo screening dell'infezione da virus dell'epatite C nella popolazione generale (studentessa: Aisa Becovic, 2023)
 - Risposta immunologica ai vaccini anti sars-cov-2 in pazienti con epatopatia cronica virale e impatto dei vaccini nella storia naturale di malattia epatica (studente: Elia Spagnolo, 2023)

THIRD MISSION

- Organizer of the "AISF Transplant Hepatologist Fellowship 2022" (Student: Armando Cutro). Host: Multivisceral Transplant Unit, Padova University Hospital.
- Organizer of the "UEG Fellowship 2023" (Student: Pavel Christopher). Host: Gastroenterology, Padova University Hospital.
- Supervisor of Dr. Victor Echavarria (fellow in Gastroenterology at the University of Santander), for a clinical and translational research fellowship in Padova (3 months)
- Organizer of the "SIGE Fellowship 2023" (Student: Valerio Buzzanca). Host: Gastroenterology, Padova University Hospital.
- Co-organizer of the "UEG Fellowship 2024" (Student: Ferdinande Kymentie). Host: Gastroenterology, Padova University Hospital.
- Co-organizer of the "UEG Fellowship 2024" (Student: Adonis Protopapas). Host: Gastroenterology, Padova University Hospital.

Padova, 05/03/2024

Alberto Zanetto

